Meeting
2022 ASCO Annual Meeting
A phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma.
Authors
Vidhya Karivedu
Division of Medical Oncology, Ohio State University, Columbus, OH
Vidhya Karivedu , Muhammad Kashif Riaz , Maria Mathews , Nicky Kurtzweil , Ilaina Monroe , Audrey Romano , Trisha Michel Wise-Draper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04313504
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS6105)
DOI
10.1200/JCO.2022.40.16_suppl.TPS6105
Abstract #
TPS6105
Poster Bd #
92b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.
First Author: Olga Zamulko
Poster
2023 ASCO Annual Meeting
Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.
First Author: Jared Cohen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trial in progress: Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated metastatic pancreatic cancer.
First Author: Robert R. McWilliams